Abstract
No public abstract is available from the verified source records.
Thomas A. Milne
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Menin-MLL inhibitors enhance JUND activity in MLLr leukemic cells, contributing to tumorigenesis and therapy resistance
10.1182/blood.2025032363 · 2026
The MLL recombinome of acute leukemias in 2017
10.1038/leu.2017.213 · 2018
The molecular functions of common and atypical MLL fusion protein complexes
10.1016/j.bbagrm.2020.194548 · 2020
Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states
10.1093/hmg/6.7.1169 · 1997
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus
10.1016/s1097-2765(04)00081-4 · 2004
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression
10.1128/mcb.24.13.5639-5649.2004 · 2004
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis
10.1016/j.cell.2005.09.025 · 2005
Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
10.1158/2159-8290.cd-16-0237 · 2016
MEN1 mutations mediate clinical resistance to menin inhibition
10.1038/s41586-023-05755-9 · 2023
Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription
10.1016/s0092-8674(00)80967-8 · 1999
No additional external references are available.